Individual name

PTO/SB/21 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no	persons are required	Patent and Tradem to respond to a collection of information	ark Offic on unles	s it displays a valid OMB control number.
		Application Number	10/7	18,982
TRANSMITT	AL	Filing Date	11/2	0/2003
FORM		First Named Inventor	Ron	L. Hale
(to be used for all correspondence after	r initial filing)	Art Unit	Not	yet known
		Examiner Name	To I	oe assigned
Total Number of Pages in This Submission		Attorney Docket Number	000	67.01R
	ENCLOSI	URES (check all that apply)	)	
Fee Transmittal Form  Fee Attached  Amendment / Reply  After Final  Affidavits/declaration(s)  Extension of Time Request  Express Abandonment Request  Information Disclosure Statement  Certified Copy of Priority Document(s)  Response to Missing Parts/ Incomplete Application  Response to Missing Parts under 37 CFR 1.52 or 1.53	Petition to Provision Power of Change of Chang	p-related Papers  o Convert a lal Application Attorney, Revocation of Correspondence  Disclaimer  for Refund  inber of CD(s)  pies, 20 pages each) erences		After Allowance communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please identify below):
SIGNATUR	RE OF APPLICA	NT, ATTORNEY, OR AGEN	T	
Firm ALEXZA MDC, 1001 or Elaine C. Stracker, P	l East Meadow C	ircle, Palo Alto, CA 9430 <b>3</b> ephone (650)-687-3905		Customer Number 37485

Signature	Hum C Ascale
Date	SEP. 2 4 2004
	CERTIFICATE OF TRANSMISSION/MAILING
	at this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the
Typed or printed	name Elaine C. Stracker
Signature	Claum C. Diche Date SEP. 2 4 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Link

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS PAPER AND THE DOCUMENTS REFERRED AS BEING ATTACHED OR ENCLOSED HEREWITH ARE BEING DEPOSITED WITH THE UNITED STATES POSTAL OFFICE ON AS EXPRESS MAIL ADDRESSED TO: MAIL STOP AMENDMENT COMMISSIONER FOR

PATENTS, PO BOX 1450, A (EXANDRIA, VA 22313-1450

Elaine C. Stracker

-- · · · · · · · ·

**PATENT** 

Attorney's Docket No.: 00067.01R

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Hale et al.

Serial No.:

10/718,982

Filed:

11/20/2003

Title

DRUG CONDENSATION AEROSOLS AND KITS

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

#### INFORMATION DISCLOSURE STATEMENT

Dear Sir:

In accordance with their continuing duty of disclosure under 37 CFR §§ §1.97, 1.98 and 1.56, Applicants hereby submit for consideration in the above-identified application the enclosed references. The Information Disclosure statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

For the convenience of the Examiner, the references are listed on a PTO Form 1449 (attached) and copies thereof are enclosed. Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines than an extension and/or other relief is required, Applicants petition for any required relief including any extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 502731**. Please direct all correspondence to the following customer number.

Respectfully submitted,

Date:

SEP. 2 4 2004

Elaine C. Stracker J.D., Ph.D., Reg. 43,166

Alexza Molecular Delivery Corporation 1001 East Meadow Circle Palo Alto, CA 94303

TEL: (650) 687-3905 FAX: (650) 687-3999

PATEOR MATION DISCLOSURE CITATION
ON AN APPLICATION

lse several sheets if necessary)

Docket Number: 00067.01R

Application Number: 10/718,982

Applicant: HALE et al.

Filing Date: 11/20/2003

Group Art Unit: Net yet known

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	02/04/1941	2,230,753	Klavehn et al.			
	2.	02/04/1941	2,230,754	Klavehn et al.			
	3.	09/01/1959	2,902,484	Horclois			
	4.	01/05/1965	3,164,600	Janssen et al.			
	5.	02/09/1965	3,169,095	Thiel et al.			
	6.	11/23/1965	3,219,533	Mullins			
	7.	11/01/1966	3,282,729	Richardson et al.			
	8.	01/03/1967	3,296,249	Bell			
	9.	01/17/1967	3,299,185	Oda et al.			
	10.	02/27/1968	3,371,085	Reeder et al.			
	11.	07/16/1968	3,393,197	Pachter			
	12.	03/18/1969	3,433,791	Bentley et al.			
	13.	02/02/1971	3,560,607	Haillty			
	14.	10/31/1972	3,701,782	Hester			
	15.	08/27/1974	3,831,606	Damani			
	16.	02/04/1975	3,864,326	Babington			
	17.	07/08/1975	3,894,040	Buzby, Jr.			
	18.	09/30/1975	3,909,463	Hartman			
	19.	03/16/1976	3,943,941	Boyd et al.			
	20.	07/27/1976	3,971,377	Damani			
	21.	09/21/1976	3,982,095	Robinson			
	22.	10/19/1976	3,987,052	Hester, Jr.			
	23.	02/22/1977	4,008,723	Borthwick et al.			
	24.	08/30/1977	4,045,156	Chu et al.			
	25.	03/21/1978	4,079,742	Rainer et al.		<u> </u>	
	26.	08/01/1978	4,104,210	Coran et al.			

EXA	۱МГ	NER:
-----	-----	------

DATE CONSIDERED:

1	_		. 1	4 4	$\sim$
ı	$H \cap T \cap T$	PTC	1_1	44	ч

## INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 00067.01R Application Number: 10/718,982

Applicant: HALE et al.

Filing Date: 11/20/2003 Group Art Unit: Net yet known

 					_	
27.	10/24/1978	4,121,583	Chen			
28.	02/27/1979	4,141,369	Burruss			
29.	07/10/1979	4,160,765	Weinstock			
30.	08/28/1979	4,166,087	Cline, et al.			
 31.	01/15/1980	4,183,912	Rosenthale			
32.	02/26/1980	4,190,654	Gherardi et al.			
 33.	04/15/1980	4,198,200	Fonda et al.			
34.	05/27/1980	Re. 30,285	Babington			
35.	08/26/1980	4,219,031	Rainer et al.			
 36.	10/21/1980	4,229,447	Porter			
37.	10/28/1980	4,229,931	Schlueter et al.			
 38.	11/04/1980	4,232,002	Nogrady			
39.	12/02/1980	4,236,544	Osaka			
40.	02/17/1981	4,251,525	Weinstock			
41.	07/28/1981	4,280,629	Slaughter			
42.	08/18/1981	4,284,089	Ray			
 43.	09/01/1981	4,286,604	Ehretsmann et al.			
44.	12/01/1981	4,303,083	Burruss, Jr.			
45.	07/20/1982	4,340,072	Bolt et al.			
46.	09/07/1982	4,347,855	Lanzillotti et al.			
47.	03/15/1983	4,376,767	Sloan			
48.	07/05/1983	4,391,285	Burnett et al.			
49.	12/27/1983	4,423,071	Chignac et al.			
50.	10/02/1984	4,474,191	Steiner			
51.	04/02/1985	4,508,726	Coleman			
52.	06/18/1985	4,523,589	Krauser			
 53.	01/28/1986	4,566,451	Badewien			
54.	05/13/1986	4,588,425	Usry et al.			
55.	05/13/1986	4,588,721	Mahan			
56.	05/27/1986	4,591,615	Aldred et al.			
57.	08/12/1986	4,605,552	Fritschi			

**EXAMINER:** 

DATE CONSIDERED:

### INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 00067.01R Application Number: 10/718,982

Applicant: HALE et al.

Filing Date: 11/20/2003 Group Art Unit: Net yet known

	58.	03/31/1987	4,654,370	Marriott, III et al.		
	59.	07/28/1987	4,683,231	Glassman		
	60.	09/15/1987	4,693,868	Katsuda et al.		
	61.	11/24/1987	4,708,151	Shelar		
	62.	12/22/1987	4,714,082	Banerjee et al.		
	63.	03/29/1988	4,734,560	Bowen		
	64.	04/05/1988	4,735,217	Gerth et al.		
	65.	04/15/1988	4,735,358	Osamo et al.		
	66.	06/28/1988	4,753,758	Miller		
	67.	07/05/1988	4,755,508	Bock et al.		
	68.	07/12/1988	4,756,318	Clearman et al.		
	69.	08/23/1988	4,765,347	Sensabaugh, Jr. et al.		
	70.	09/20/1988	4,771,795	White et al.		
_	71.	10/04/1988	4,774,971	Vieten		
	72.	12/27/1988	4,793,365	Sensabaugh, Jr. et al.		
-	73.	12/27/1988	4,793,366	Hill		
	74.	01/31/1989	4,800,903	Ray et al.		
	75.	01/31/1989	4,801,411	Wellinghoff et al.		
	76.	03/21/1989	4,814,161	Jinks et al.		
	77.	04/11/1989	4,819,665	Roberts et al.		
	78.	07/18/1989	4,848,374	Chard et al.		
	79.	08/01/1989	4,852,561	Sperry		
	80.	08/01/1989	4,853,517	Bowen et al.		
	81.	08/08/1989	4,854,331	Banerjee et al.		•
	82.	08/22/1989	4,858,630	Banerjee et al.		
	83.	09/05/1989	4,863,720	Burghart et al.		
	84.	11/21/1989	4,881,541	Eger et al.		
•	85.	11/21/1989	4,881,556	Clearman et al.		
	86.	12/26/1989	4,889,850	Thornfeldt et al.		
	87.	01/23/1990	4,895,719	Radhakrishnun et al.		
	88.	03/06/1990	4,906,417	Gentry		

**EXAMINER:** 

DATE CONSIDERED:

### INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 00067.01R Application Number: 10/718,982

Applicant: HALE et al.

Filing Date: 11/20/2003 Group Art Unit: Net yet known

89.	04/17/1990	4,917,119	Potter et al.		
90.	04/17/1990	4,917,120	Hill		
 91.	04/17/1990	4,917,830	Ortiz et al.		
 92.	05/08/1990	4,922,901	Brooks et al.		
 93.	05/29/1990	4,928,714	Shannon		
94.	07/17/1990	4,941,483	Ridings et al.		
95.	08/14/1990	4,947,874	Brooks et al.		
96.	08/14/1990	4,947,875	Brooks et al.		
97.	08/21/1990	4,950,664	Goldberg		
 98.	09/11/1990	4,955,945	Weick		
 99.	09/25/1990	4,959,380	Wilson		
 100.	10/16/1990	4,963,289	Ortiz et al.		
 101.	02/05/1991	4,989,619	Clearman et al.		
102.	05/21/1991	5,016,425	Weick		
103.	05/21/1991	5,017,575	Golwyn		
104.	05/28/1991	5,019,122	Clearman et al.		
105.	06/04/1991	5,020,548	Farrier et al.		
106.	07/02/1991	5,027,836	Shannon et al.		
107.	07/23/1991	5,033,483	Clearman et al.		 
108.	08/27/1991	5,042,509	Banerjee et al.		
109.	09/17/1991	5,049,389	Radhakrishnun		
110.	10/29/1991	5,060,666	Clearman et al.		
111.	10/29/1991	5,060,667	Strubel		
 112.	10/29/1991	5,060,671	Counts et al.	_	
113.	11/26/1991	5,067,499	Banerjee et al.		
114.	12/17/1991	5,072,726	Mazloomdoost et al.		
115.	12/31/1991	5,076,292	Sensabaugh, Jr. et al.		
116.	03/31/1992	5,099,861	Clearman et al.		
117.	04/21/1992	5,105,831	Banerjee et al.		
118.	05/12/1992	5,112,598	Biesalski		
119.	06/02/1992	5,118,494	Schultz et al.		

**EXAMINER:** 

DATE CONSIDERED:

## INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 00067.01R Appl

Application Number: 10/718,982

Applicant: HALE et al.

Filing Date: 11/20/2003 Group Art Unit: Net yet known

120.	06/09/1992	5,119,834	Shannon et al.	
121.	06/30/1992	5,126,123	Johnson	
122.	07/28/1992	5,133,368	Neumann et al.	
 123.	08/11/1992	5,137,034	Perfetti et al.	
124.	10/20/1992	5,156,170	Clearman et al.	
 125.	11/17/1992	5,164,740	Ivri	
126.	11/24/1992	5,166,202	Schweizer	
127.	12/01/1992	5,167,242	Turner et al.	
128.	01/05/1993	5,177,071	Freidinger et al.	
129.	02/16/1993	5,186,164	Raghuprasad	
 130.	03/09/1993	5,192,548	Velasquez et al.	
 131.	07/06/1993	5,224,498	Deevi et al.	
132.	07/20/1993	5,229,120	DeVincent	
 133.	07/20/1993	5,229,382	Chakrabarti et al.	
134.	08/31/1993	5,240,922	O'Neill	
 135.	10/05/1993	5,249,586	Morgan et al.	
 136.	11/23/1993	5,264,433	Sato et al.	
137.	02/08/1994	5,284,133	Burns et al.	
138.	03/08/1994	5,292,499	Evans et al.	
139.	07/26/1994	5,333,106	Lanpher et al.	
140.	09/13/1994	5,345,951	Serrano et al.	
141.	11/15/1994	5,364,838	Rubsamen	
142.	11/22/1994	5,366,770	Wang	
143.	12/27/1994	5,376,386	Ganderton et al.	
144.	02/14/1995	5,388,574	Ingebrethsen	
145.	02/21/1995	5,391,081	Lampotang et al.	
146.	03/21/1995	5,399,574	Robertson et al.	
147.	03/28/1995	5,400,808	Turner et al.	
148.	07/25/1995	5,436,230	Soudant, et al.	
149.	09/19/1995	5,451,408	Mezei et al.	
150.	10/03/1995	5,455,043	Fischel-Ghodsian	

**EXAMINER:** 

DATE CONSIDERED:

### INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 00067.01R Application Number: 10/718,982

Applicant: HALE et al.

Filing Date: 11/20/2003 Group Art Unit: Net yet known

_	151.	10/10/1995	5,456,247	Shilling et al.		
	152.	10/10/1995	5,456,677	Spector		
	153.	10/10/1995	5,457,100	Daniel		
	154.	10/10/1995	5,457,101	Greenwood et al.		
	155.	10/17/1995	5,459,137	Andrasi et al.		
	156.	10/31/1995	5,462,740	Evenstad et al.		
	157.	11/21/1995	5,468,936	Deevi et al.		,
	158.	03/26/1996	5,501,236	Hill et al.		
	159.	04/16/1996	5,507,277	Rubsamen et al.		
	160.	04/30/1996	5,511,726	Greenspan et al.		
	161.	05/21/1996	5,519,019	Andrasi et al.		
	162.	06/11/1996	5,525,329	Snyder, et al.		
	163.	07/30/1996	5,540,959	Wang		
	164.	08/06/1996	5,543,434	Weg		
	165.	08/13/1996	5,544,646	Lloyd et al.		
	166.	12/17/1996	5,584,701	Lampotang et al.		
,	167.	12/24/1996	5,586,550	Ivri et al.		
	168.	01/14/1997	5,592,934	Thwaites		
	169.	02/25/1997	5,605,146	Sarela		
	170.	02/25/1997	5,605,897	Beasley, Jr. et al.		
	171.	03/04/1997	5,607,691	Hale et al.		
	172.	04/15/1997	5,619,984	Hodson et al.		
	173.	04/22/1997	5,622,944	Hale et al.		
	174.	05/06/1997	5,627,178	Chakrabarti et al.		
	175.	07/22/1997	5,649,554	Sprinkel		
	176.	08/12/1997	5,655,523	Hodson et al.		
	177.	08/12/1997	5,656,255	Jones		
	178.	08/26/1997	5,660,166	Lloyd et al.		
	179.	09/16/1997	5,666,977	Higgins et al.		
	180.	11/25/1997	5,690,809	Subramaniam et al.		
	181.	12/09/1997	5,694,919	Rubsamen et al.		

**EXAMINER:** 

DATE CONSIDERED:

### INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 00067.01R Application Number: 10/718,982

Applicant: HALE et al.

Filing Date: 11/20/2003 Group Art Unit: Net yet known

		T ====================================	1	<del></del>	
182		5,718,222	Lloyd et al.	<u> </u>	
183		5,724,957	Rubsamen et al.		
184	. 03/10/1998	5,725,756	Subramaniam et al.		
185	. 03/31/1998	5,733,572	Unger et al.		
186	. 04/07/1998	5,735,263	Rubsamen et al.		
187	. 04/14/1998	5,738,865	Baichwal et al.		
188	. 04/14/1998	5,738,865	Baichwal et al.		
189	. 04/28/1998	5,743,250	Gonda et al.		
190	04/28/1998	5,743,251	Howell et al.		
191	04/28/1998	5,744,469	Tran		
192	05/05/1998	5,747,001	Wiedmann et al.		
193	05/26/1998	5,756,449	Andersen et al.		
194	06/02/1998	5,758,637	Ivri et al.		
195	06/16/1998	5,767,117	Moskowitz et al.		·
196	06/23/1998	5,770,222	Unger et al.		
197	06/30/1998	5,771,882	Psaros et al.		
198	07/07/1998	5,776,928	Beasley, Jr.		
199	09/08/1998	5,804,212	Illum		
200	10/06/1998	5,817,656	Beasley, Jr. et al.		
201	10/13/1998	5,819,756	Mielordt		
202	10/20/1998	5,823,178	Lloyd et al.		
203	11/10/1998	5,833,891	Subramaniam et al.		
204	11/24/1998	5,840,246	Hammons et al.		
205	01/05/1999	5,855,564	Ruskewicz		
206	01/05/1999	5,855,913	Hanes et al.		
207	. 02/23/1999	5,874,064	Edwards et al.		
208	03/02/1999	5,875,776	Vaghefi		
209	. 03/09/1999	5,878,752	Adams et al.		
210	03/23/1999	5,884,620	Gonda et al.		
211	04/06/1999	5,890,908	Lampotang et al.		
212	04/20/1999	5,894,841	Voges		

EXAMINER:

DATE CONSIDERED:

# INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Application Number: 10/718,982
Group Art Unit: Net yet known

213.	05/25/1999	5,906,811	Hersh	
214.	05/25/1999	5,907,075	Subramaniam et al.	
215.	06/08/1999	5,910,301	Farr et al.	
216.	06/29/1999	5,915,378	Lloyd et al.	
217.	07/06/1999	5,918,595	Olsson	
218.	07/27/1999	5,928,520	Haumesser	
 219.	07/27/1999	5,929,093	Pang et al.	
220.	08/10/1999	5,934,272	Lloyd et al.	
221.	08/10/1999	5,935,604	Illum	
222.	08/17/1999	5,938,117	Ivri	
223.	08/17/1999	5,939,100	Albrechtsen et al.	
224.	08/24/1999	5,941,240	Gonda et al.	
225.	08/31/1999	5,944,012	Pera	
 226.	09/28/1999	5,957,124	Lloyd et al.	
227.	10/05/1999	5,960,792	Lloyd et al.	
228.	10/26/1999	5,970,973	Gonda et al.	
229.	10/26/1999	5,971,951	Ruskewicz	
230.	11/16/1999	5,985,309	Edwards et al.	
231.	11/30/1999	5,993,805	Sutton et al.	
232.	11/30/1999	5,993,805	Sutton et al.	
233.	12/21/1999	6,004,970	O'Malley et al.	
234.	12/28/1999	6,008,214	Kwon et al.	
235.	12/28/1999	6,008,216	Chakrabarti et al.	
236.	01/11/2000	6,013,050	Bellhouse et al.	
237.	01/18/2000	6,014,969	Lloyd et al.	
238.	01/18/2000	6,014,970	Ivri et al.	
239.	03/28/2000	6,041,777	Faithfull et al.	
240.	04/04/2000	6,044,777	Walsh	
241.	04/11/2000	6,048,550	Chan et al.	_
242.	04/11/2000	6,048,857	Ellinwood, Jr. et al.	
243.	04/18/2000	6,050,260	Daniell et al.	

DATE CONSIDERED:

### INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 00067.01R Application Number: 10/718,982

Applicant: HALE et al.

Filing Date: 11/20/2003 Group Art Unit: Net yet known

	244.	04/18/2000	6,051,257	Kodas et al.	
	245.	04/18/2000	6,051,566	Bianco	
	246.	06/20/2000	Re. 36,744	Goldberg	
	247.	07/18/2000	6,089,857	Matsuura et al.	
	248.	07/18/2000	6,090,403	Block et al.	
	249.	08/01/2000	6,095,134	Sievers et al.	
	250.	08/01/2000	6,095,153	Kessler et al.	
	251.	08/08/2000	6,098,620	Lloyd et al.	
	252.	08/15/2000	6,102,036	Slutsky et al.	
	253.	09/05/2000	6,113,795	Subramaniam et al.	
	254.	09/12/2000	6,117,866	Bondinell et al.	
	255.	10/03/2000	6,125,853	Susa et al.	
	256.	10/03/2000	6,126,919	Stefely et al.	
	257.	10/17/2000	6,131,566	Ashurst et al.	
-	258.	10/17/2000	6,131,570	Schuster et al.	
	259.	10/17/2000	6,133,327	Kimura et al.	
	260.	10/24/2000	6,135,369	Prendergast et al.	
	261.	10/24/2000	6,136,295	Edwards et al.	
	262.	10/31/2000	6,138,683	Hersh et al.	
	263.	10/31/2000	6,140,323	Ellinwood, Jr. et al.	
	264.	11/07/2000	6,143,277	Ashurst et al.	
	265.	11/07/2000	6,143,746	Daugan et al.	
	266.	11/21/2000	6,149,892	Britto	
	267.	01/02/2001	6,167,880	Gonda et al.	
	268.	05/22/2001	6,234,167	Cox et al.	
	269.	06/05/2001	6,241,969	Saidi et al.	
	270.	07/03/2001	6,255,334	Sands	
	271.	07/24/2001	6,263,872	Schuster et al.	
	272.	07/24/2001	6,264,922	Wood et al.	
	273.	09/04/2001	6,284,287	Sarlikiotis et al.	
	274.	10/09/2001	6,299,900	Reed et al.	

**EXAMINER:** 

DATE CONSIDERED:

### INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 00067.01R	Application Number: 10/718,982			
Applicant: HALE et al.				

Filing Date: 11/20/2003 Group Art Unit: Net yet known

	275.	10/23/2001	6,306,431	Zhang et al.	
	276.	11/06/2001	6,313,176	Ellinwood, Jr. et al.	
	277.	04/23/2002	6,376,550	Raber et al.	·
	278.	06/25/2002	6,408,854	Gonda et al.	
	279.	07/02/2002	6,413,930	Ratti et al.	
	280.	07/16/2002	6,420,351	Tsai et al.	
	281.	08/13/2002	6,431,166	Gonda et al.	
	282.	09/03/2002	6,443,152	Lockhart et al.	
	283.	10/08/2002	6,461,591	Keller et al.	
	284.	01/14/2003	6,506,762	Horvath et al.	
	285.	02/04/2003	6,514,482	Bartus et al.	
	286.	02/11/2003	6,516,796	Cox et al.	
	287.	07/15/2003	6,591,839	Meyer et al.	
·	288.	10/14/2003	6,632,047	Vinegar	
	289.	09/06/2001	US 2001/0020147	Staniforth et al.	
	290.	03/14/2002	US 2002/0031480	Peart, et al.	
	291.	03/28/2002	US 2002/0037828	Wilson et al.	
	292.	05/16/2002	US 2002/0058009	Bartus et al.	
	293.	05/23/2002	US 2002/0061281	Osbakken et al.	
	294.	07/04/2002	US 2002/0086852	Cantor	
	295.	08/22/2002	US 2002/0112723	Schuster et al.	
	296.	11/28/2002	US 2002/0176841	Barker et al.	
	297.	01/02/2003	US 2003/0004142	Prior et al.	
	298.	02/13/2003	US2003/0032638	Kim et al.	

#### RELATED ALEXZA MOLECULAR DELIVERY CORPORATION PATENT DOCUMENTS

 299.	08/04/2003	10/633,876	Hale et al.	
300.	08/04/2003	10/633,877	Hale et al.	
 301.	12/30/2003	10/749,537	Rabinowitz et al.	
302.	12/30/2003	10/749,539	Rabinowitz et al.	

EXAMINER:	DATE CONSIDERED:

### INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 00067.01R

Application Number: 10/718,982

Applicant: HALE et al.

Filing Date: 11/20/2003

Group Art Unit: Net yet known

303. 01/27/2004 10/766,49 Rabinowitz et al. 304. 01/27/2004 10/766,566 Rabinowitz et al. 305. 01/27/2004 10/766,566 Rabinowitz et al. 306. 01/27/2004 10/766,567 Rabinowitz et al. 307. 01/27/2004 10/766,634 Rabinowitz et al. 308. 01/27/2004 10/766,647 Rabinowitz et al. 309. 01/28/2004 10/767,115 Rabinowitz et al. 310. 01/29/2004 10/768,205 Rabinowitz et al. 311. 01/29/2004 10/768,205 Rabinowitz et al. 312. 01/29/2004 10/768,281 Rabinowitz et al. 313. 01/29/2004 10/768,282 Rabinowitz et al. 314. 01/29/2004 10/768,293 Rabinowitz et al. 315. 01/30/2004 10/769,046 Rabinowitz et al. 316. 01/29/2004 10/769,051 Rabinowitz et al. 317. 01/29/2004 10/769,051 Rabinowitz et al. 318. 01/29/2004 10/769,157 Rabinowitz et al. 319. 02/09/2004 10/769,157 Rabinowitz et al. 319. 02/09/2004 10/769,157 Rabinowitz et al. 319. 02/09/2004 10/769,157 Rabinowitz et al. 320. 03/03/2004 10/775,586 Rabinowitz et al. 320. 03/03/2004 10/779,1915 Hale et al. 321. 03/03/2004 10/792,012 Hale et al. 322. 03/03/2004 10/792,012 Hale et al. 323. 03/03/2004 10/792,013 Rabinowitz et al. 324. 03/03/2004 10/792,013 Rabinowitz et al. 325. 03/03/2004 10/792,013 Rabinowitz et al. 326. 03/31/2004 10/792,013 Rabinowitz et al. 327. 03/03/2004 10/792,013 Rabinowitz et al. 328. 03/03/2004 10/792,013 Rabinowitz et al. 329. 03/03/2004 10/792,013 Rabinowitz et al. 321. 03/03/2004 10/792,013 Rabinowitz et al. 327. 03/03/2004 10/792,013 Rabinowitz et al. 328. 03/03/2004 10/792,0296 Hale et al. 329. 03/03/2004 10/792,0296 Hale et al. 329. 03/03/2004 10/792,0296 Rabinowitz et al. 329. 03/03/2004 10/813,721 Rabinowitz et al. 329. 03/03/2004 10/813,721 Rabinowitz et al. 329. 03/03/2004 10/814,690 Rabinowitz et al. 329. 03/03/2004 10/816,690 Rabinowitz et al. 329				
305. 01/27/2004	303.	01/27/2004	10/766,149	Rabinowitz et al.
306. 01/27/2004	304.	01/27/2004	10/766,279	Rabinowitz et al.
307. 01/27/2004	305.	01/27/2004	10/766,566	Rabinowitz et al.
308.         01/27/2004         10/766,647         Rabinowitz et al.           309.         01/28/2004         10/767,115         Rabinowitz et al.           310.         01/29/2004         10/768,205         Rabinowitz et al.           311.         01/29/2004         10/768,220         Rabinowitz et al.           312.         01/29/2004         10/768,281         Rabinowitz et al.           313.         01/29/2004         10/769,046         Rabinowitz et al.           314.         01/30/2004         10/769,046         Rabinowitz et al.           315.         01/30/2004         10/769,051         Rabinowitz et al.           316.         01/29/2004         10/769,157         Rabinowitz et al.           317.         01/29/2004         10/769,197         Rabinowitz et al.           318.         02/09/2004         10/775,583         Rabinowitz et al.           319.         02/09/2004         10/775,586         Rabinowitz et al.           320.         03/03/2004         10/791,915         Hale et al.           321.         03/03/2004         10/792,012         Hale et al.           322.         03/03/2004         10/792,013         Rabinowitz et al.           323.         03/03/2004         10/79	306.	01/27/2004	10/766,574	Rabinowitz et al.
309. 01/28/2004 10/767,115 Rabinowitz et al. 310. 01/29/2004 10/768,205 Rabinowitz et al. 311. 01/29/2004 10/768,220 Rabinowitz et al. 312. 01/29/2004 10/768,281 Rabinowitz et al. 313. 01/29/2004 10/768,293 Rabinowitz et al. 314. 01/30/2004 10/769,046 Rabinowitz et al. 315. 01/30/2004 10/769,051 Rabinowitz et al. 316. 01/29/2004 10/769,157 Rabinowitz et al. 317. 01/29/2004 10/769,197 Rabinowitz et al. 318. 02/09/2004 10/775,583 Rabinowitz et al. 319. 02/09/2004 10/775,586 Rabinowitz et al. 320. 03/03/2004 10/791,915 Hale et al. 321. 03/03/2004 10/792,001 Rabinowitz et al. 322. 03/03/2004 10/792,012 Hale et al. 323. 03/03/2004 10/792,012 Hale et al. 324. 03/03/2004 10/792,03 Rabinowitz et al. 325. 03/03/2004 10/792,096 Hale et al. 326. 03/31/2004 10/792,239 Hale et al. 327. 03/31/2004 10/813,721 Rabinowitz et al. 328. 03/31/2004 10/813,722 Rabinowitz et al. 329. 03/31/2004 10/813,722 Rabinowitz et al. 329. 03/31/2004 10/813,722 Rabinowitz et al. 329. 03/31/2004 10/813,722 Rabinowitz et al. 330. 04/01/2004 10/814,690 Rabinowitz et al. 331. 04/01/2004 10/815,527 Rabinowitz et al. 332. 04/01/2004 10/816,492 Rabinowitz et al.	307.	01/27/2004	10/766,634	Rabinowitz et al.
310. 01/29/2004	308.	01/27/2004	10/766,647	Rabinowitz et al.
311. 01/29/2004 10/768,220 Rabinowitz et al.  312. 01/29/2004 10/768,281 Rabinowitz et al.  313. 01/29/2004 10/768,293 Rabinowitz et al.  314. 01/30/2004 10/769,046 Rabinowitz et al.  315. 01/30/2004 10/769,051 Rabinowitz et al.  316. 01/29/2004 10/769,157 Rabinowitz et al.  317. 01/29/2004 10/769,197 Rabinowitz et al.  318. 02/09/2004 10/775,583 Rabinowitz et al.  319. 02/09/2004 10/775,586 Rabinowitz et al.  320. 03/03/2004 10/791,915 Hale et al.  321. 03/03/2004 10/792,001 Rabinowitz et al.  322. 03/03/2004 10/792,012 Hale et al.  323. 03/03/2004 10/792,013 Rabinowitz et al.  324. 03/03/2004 10/792,013 Rabinowitz et al.  325. 03/03/2004 10/792,096 Hale et al.  326. 03/31/2004 10/792,239 Hale et al.  327. 03/31/2004 10/813,721 Rabinowitz et al.  328. 03/31/2004 10/813,722 Rabinowitz et al.  329. 03/31/2004 10/813,722 Rabinowitz et al.  329. 03/31/2004 10/813,722 Rabinowitz et al.  330. 04/01/2004 10/814,690 Rabinowitz et al.  331. 04/01/2004 10/815,527 Rabinowitz et al.  332. 04/01/2004 10/816,407 Rabinowitz et al.  332. 04/01/2004 10/816,407 Rabinowitz et al.	309.	01/28/2004	10/767,115	Rabinowitz et al.
312. 01/29/2004 10/768,281 Rabinowitz et al.  313. 01/29/2004 10/768,293 Rabinowitz et al.  314. 01/30/2004 10/769,046 Rabinowitz et al.  315. 01/30/2004 10/769,051 Rabinowitz et al.  316. 01/29/2004 10/769,157 Rabinowitz et al.  317. 01/29/2004 10/769,197 Rabinowitz et al.  318. 02/09/2004 10/775,583 Rabinowitz et al.  319. 02/09/2004 10/775,586 Rabinowitz et al.  320. 03/03/2004 10/791,915 Hale et al.  321. 03/03/2004 10/792,001 Rabinowitz et al.  322. 03/03/2004 10/792,012 Hale et al.  323. 03/03/2004 10/792,013 Rabinowitz et al.  324. 03/03/2004 10/792,013 Rabinowitz et al.  325. 03/03/2004 10/792,096 Hale et al.  326. 03/31/2004 10/792,239 Hale et al.  327. 03/31/2004 10/813,721 Rabinowitz et al.  328. 03/31/2004 10/813,722 Rabinowitz et al.  329. 03/31/2004 10/813,722 Rabinowitz et al.  329. 03/31/2004 10/814,690 Rabinowitz et al.  330. 04/01/2004 10/814,998 Rabinowitz et al.  331. 04/01/2004 10/815,527 Rabinowitz et al.  332. 04/01/2004 10/816,407 Rabinowitz et al.	310.	01/29/2004	10/768,205	Rabinowitz et al.
313. 01/29/2004 10/768,293 Rabinowitz et al.  314. 01/30/2004 10/769,046 Rabinowitz et al.  315. 01/30/2004 10/769,051 Rabinowitz et al.  316. 01/29/2004 10/769,157 Rabinowitz et al.  317. 01/29/2004 10/769,197 Rabinowitz et al.  318. 02/09/2004 10/775,583 Rabinowitz et al.  319. 02/09/2004 10/775,586 Rabinowitz et al.  320. 03/03/2004 10/791,915 Hale et al.  321. 03/03/2004 10/792,001 Rabinowitz et al.  322. 03/03/2004 10/792,012 Hale et al.  323. 03/03/2004 10/792,013 Rabinowitz et al.  324. 03/03/2004 10/792,013 Rabinowitz et al.  325. 03/03/2004 10/792,096 Hale et al.  326. 03/31/2004 10/792,239 Hale et al.  327. 03/31/2004 10/813,721 Rabinowitz et al.  328. 03/31/2004 10/813,722 Rabinowitz et al.  329. 03/31/2004 10/813,722 Rabinowitz et al.  329. 03/31/2004 10/814,690 Rabinowitz et al.  330. 04/01/2004 10/814,690 Rabinowitz et al.  331. 04/01/2004 10/815,527 Rabinowitz et al.  331. 04/01/2004 10/816,407 Rabinowitz et al.  332. 04/01/2004 10/816,407 Rabinowitz et al.	311.	01/29/2004	10/768,220	Rabinowitz et al.
314.       01/30/2004       10/769,046       Rabinowitz et al.         315.       01/30/2004       10/769,051       Rabinowitz et al.         316.       01/29/2004       10/769,157       Rabinowitz et al.         317.       01/29/2004       10/769,197       Rabinowitz et al.         318.       02/09/2004       10/775,583       Rabinowitz et al.         319.       02/09/2004       10/775,586       Rabinowitz et al.         320.       03/03/2004       10/791,915       Hale et al.         321.       03/03/2004       10/792,001       Rabinowitz et al.         322.       03/03/2004       10/792,012       Hale et al.         323.       03/03/2004       10/792,013       Rabinowitz et al.         324.       03/03/2004       10/792,096       Hale et al.         325.       03/03/2004       10/792,239       Hale et al.         326.       03/31/2004       10/813,721       Rabinowitz et al.         327.       03/31/2004       10/813,722       Rabinowitz et al.         328.       03/31/2004       10/814,690       Rabinowitz et al.         329.       03/31/2004       10/816,490       Rabinowitz et al.         330.       04/01/2004       10/815,52	312.	01/29/2004	10/768,281	Rabinowitz et al.
315.   01/30/2004   10/769,051   Rabinowitz et al.	313.	01/29/2004	10/768,293	Rabinowitz et al.
316. 01/29/2004 10/769,157 Rabinowitz et al.  317. 01/29/2004 10/769,197 Rabinowitz et al.  318. 02/09/2004 10/775,583 Rabinowitz et al.  319. 02/09/2004 10/775,586 Rabinowitz et al.  320. 03/03/2004 10/791,915 Hale et al.  321. 03/03/2004 10/792,001 Rabinowitz et al.  322. 03/03/2004 10/792,012 Hale et al.  323. 03/03/2004 10/792,013 Rabinowitz et al.  324. 03/03/2004 10/792,013 Rabinowitz et al.  325. 03/03/2004 10/792,096 Hale et al.  326. 03/03/2004 10/792,239 Hale et al.  327. 03/31/2004 10/813,721 Rabinowitz et al.  328. 03/31/2004 10/813,722 Rabinowitz et al.  329. 03/31/2004 10/814,690 Rabinowitz et al.  329. 03/31/2004 10/814,998 Rabinowitz et al.  330. 04/01/2004 10/815,527 Rabinowitz et al.  331. 04/01/2004 10/816,492 Rabinowitz et al.	314.	01/30/2004	10/769,046	Rabinowitz et al.
317. 01/29/2004 10/769,197 Rabinowitz et al.  318. 02/09/2004 10/775,583 Rabinowitz et al.  319. 02/09/2004 10/775,586 Rabinowitz et al.  320. 03/03/2004 10/791,915 Hale et al.  321. 03/03/2004 10/792,001 Rabinowitz et al.  322. 03/03/2004 10/792,012 Hale et al.  323. 03/03/2004 10/792,013 Rabinowitz et al.  324. 03/03/2004 10/792,013 Rabinowitz et al.  325. 03/03/2004 10/792,096 Hale et al.  326. 03/03/2004 10/792,239 Hale et al.  327. 03/31/2004 10/813,721 Rabinowitz et al.  328. 03/31/2004 10/813,722 Rabinowitz et al.  329. 03/31/2004 10/814,690 Rabinowitz et al.  329. 03/31/2004 10/814,998 Rabinowitz et al.  330. 04/01/2004 10/815,527 Rabinowitz et al.  331. 04/01/2004 10/816,407 Rabinowitz et al.  332. 04/01/2004 10/816,492 Rabinowitz et al.	315.	01/30/2004	10/769,051	Rabinowitz et al.
318. 02/09/2004 10/775,583 Rabinowitz et al.  319. 02/09/2004 10/775,586 Rabinowitz et al.  320. 03/03/2004 10/791,915 Hale et al.  321. 03/03/2004 10/792,001 Rabinowitz et al.  322. 03/03/2004 10/792,012 Hale et al.  323. 03/03/2004 10/792,013 Rabinowitz et al.  324. 03/03/2004 10/792,096 Hale et al.  325. 03/03/2004 10/792,239 Hale et al.  326. 03/31/2004 10/813,721 Rabinowitz et al.  327. 03/31/2004 10/813,722 Rabinowitz et al.  328. 03/31/2004 10/813,722 Rabinowitz et al.  329. 03/31/2004 10/814,690 Rabinowitz et al.  329. 03/31/2004 10/814,998 Rabinowitz et al.  330. 04/01/2004 10/815,527 Rabinowitz et al.  331. 04/01/2004 10/816,407 Rabinowitz et al.  332. 04/01/2004 10/816,492 Rabinowitz et al.	316.	01/29/2004	10/769,157	Rabinowitz et al.
319.	317.	01/29/2004	10/769,197	Rabinowitz et al.
320. 03/03/2004   10/791,915   Hale et al.     321. 03/03/2004   10/792,001   Rabinowitz et al.     322. 03/03/2004   10/792,012   Hale et al.     323. 03/03/2004   10/792,013   Rabinowitz et al.     324. 03/03/2004   10/792,096   Hale et al.     325. 03/03/2004   10/792,239   Hale et al.     326. 03/31/2004   10/813,721   Rabinowitz et al.     327. 03/31/2004   10/813,722   Rabinowitz et al.     328. 03/31/2004   10/814,690   Rabinowitz et al.     329. 03/31/2004   10/814,998   Rabinowitz et al.     330. 04/01/2004   10/815,527   Rabinowitz et al.     331. 04/01/2004   10/816,407   Rabinowitz et al.     332. 04/01/2004   10/816,492   Rabinowitz et al.	318.	02/09/2004	10/775,583	Rabinowitz et al.
321.   03/03/2004   10/792,001   Rabinowitz et al.	319.	02/09/2004	10/775,586	Rabinowitz et al.
322.       03/03/2004       10/792,012       Hale et al.         323.       03/03/2004       10/792,013       Rabinowitz et al.         324.       03/03/2004       10/792,096       Hale et al.         325.       03/03/2004       10/792,239       Hale et al.         326.       03/31/2004       10/813,721       Rabinowitz et al.         327.       03/31/2004       10/813,722       Rabinowitz et al.         328.       03/31/2004       10/814,690       Rabinowitz et al.         329.       03/31/2004       10/814,998       Rabinowitz et al.         330.       04/01/2004       10/815,527       Rabinowitz et al.         331.       04/01/2004       10/816,407       Rabinowitz et al.         332.       04/01/2004       10/816,492       Rabinowitz et al.	320.	03/03/2004	10/791,915	Hale et al.
323.       03/03/2004       10/792,013       Rabinowitz et al.         324.       03/03/2004       10/792,096       Hale et al.         325.       03/03/2004       10/792,239       Hale et al.         326.       03/31/2004       10/813,721       Rabinowitz et al.         327.       03/31/2004       10/813,722       Rabinowitz et al.         328.       03/31/2004       10/814,690       Rabinowitz et al.         329.       03/31/2004       10/814,998       Rabinowitz et al.         330.       04/01/2004       10/815,527       Rabinowitz et al.         331.       04/01/2004       10/816,407       Rabinowitz et al.         332.       04/01/2004       10/816,492       Rabinowitz et al.	321.	03/03/2004	10/792,001	Rabinowitz et al.
324.       03/03/2004       10/792,096       Hale et al.         325.       03/03/2004       10/792,239       Hale et al.         326.       03/31/2004       10/813,721       Rabinowitz et al.         327.       03/31/2004       10/813,722       Rabinowitz et al.         328.       03/31/2004       10/814,690       Rabinowitz et al.         329.       03/31/2004       10/814,998       Rabinowitz et al.         330.       04/01/2004       10/815,527       Rabinowitz et al.         331.       04/01/2004       10/816,407       Rabinowitz et al.         332.       04/01/2004       10/816,492       Rabinowitz et al.	322.	03/03/2004	10/792,012	Hale et al.
325.       03/03/2004       10/792,239       Hale et al.         326.       03/31/2004       10/813,721       Rabinowitz et al.         327.       03/31/2004       10/813,722       Rabinowitz et al.         328.       03/31/2004       10/814,690       Rabinowitz et al.         329.       03/31/2004       10/814,998       Rabinowitz et al.         330.       04/01/2004       10/815,527       Rabinowitz et al.         331.       04/01/2004       10/816,407       Rabinowitz et al.         332.       04/01/2004       10/816,492       Rabinowitz et al.	323.	03/03/2004	10/792,013	Rabinowitz et al.
326.       03/31/2004       10/813,721       Rabinowitz et al.         327.       03/31/2004       10/813,722       Rabinowitz et al.         328.       03/31/2004       10/814,690       Rabinowitz et al.         329.       03/31/2004       10/814,998       Rabinowitz et al.         330.       04/01/2004       10/815,527       Rabinowitz et al.         331.       04/01/2004       10/816,407       Rabinowitz et al.         332.       04/01/2004       10/816,492       Rabinowitz et al.	324.	03/03/2004	10/792,096	Hale et al.
327.       03/31/2004       10/813,722       Rabinowitz et al.         328.       03/31/2004       10/814,690       Rabinowitz et al.         329.       03/31/2004       10/814,998       Rabinowitz et al.         330.       04/01/2004       10/815,527       Rabinowitz et al.         331.       04/01/2004       10/816,407       Rabinowitz et al.         332.       04/01/2004       10/816,492       Rabinowitz et al.	325.	03/03/2004	10/792,239	Hale et al.
328.       03/31/2004       10/814,690       Rabinowitz et al.         329.       03/31/2004       10/814,998       Rabinowitz et al.         330.       04/01/2004       10/815,527       Rabinowitz et al.         331.       04/01/2004       10/816,407       Rabinowitz et al.         332.       04/01/2004       10/816,492       Rabinowitz et al.	326.	03/31/2004	10/813,721	Rabinowitz et al.
329.       03/31/2004       10/814,998       Rabinowitz et al.         330.       04/01/2004       10/815,527       Rabinowitz et al.         331.       04/01/2004       10/816,407       Rabinowitz et al.         332.       04/01/2004       10/816,492       Rabinowitz et al.	327.	03/31/2004	10/813,722	Rabinowitz et al.
330.       04/01/2004       10/815,527       Rabinowitz et al.         331.       04/01/2004       10/816,407       Rabinowitz et al.         332.       04/01/2004       10/816,492       Rabinowitz et al.	328.	03/31/2004	10/814,690	Rabinowitz et al.
331.   04/01/2004   10/816,407   Rabinowitz et al.	329.	03/31/2004	10/814,998	Rabinowitz et al.
332. 04/01/2004 10/816,492 Rabinowitz et al.	330.	04/01/2004	10/815,527	Rabinowitz et al.
	331.	04/01/2004	10/816,407	Rabinowitz et al.
333. 04/01/2004 10/816,567 Rabinowitz et al.	332.	04/01/2004	10/816,492	Rabinowitz et al.
	333.	04/01/2004	10/816,567	Rabinowitz et al.

**EXAMINER:** 

DATE CONSIDERED:

### INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 00067.01R	Application Number: 10/718,982		
Applicant: HALE et al.			
Filing Date: 11/20/2003	Group Art Unit: Net yet known		

	1		
334.	08/04/2004	10/912,462	Hale et al.
335.	01/23/2003	US 2003/0015196	Hodges et al.
336.	04/03/2003	US 2003/0062042	Wensley et al.
337.	11/13/2003	US 2003/0209240	Hale et al.
338.	01/02/2003	US 2003/0000518	Rabinowitz et al.
339.	01/09/2003	US 2003/0005924	Rabinowitz et al.
340.	01/09/2003	US 2003/0005925	Hale et al.
341.	01/09/2003	US 2003/0007933	Rabinowitz et al.
342.	01/09/2003	US 2003/0007934	Rabinowitz et al.
343.	01/16/2003	US 2003/0012737	Rabinowitz et al.
344.	01/16/2003	US 2003/0012738	Rabinowitz et al.
345.	1/16/2003	US 2003/0012740	Rabinowitz et al.
346.	01/23/2003	US 2003/0015189	Rabinowitz et al.
347.	01/23/2003	US 2003/0015190	Rabinowitz et al.
348.	01/23/2003	US 2003/0017114	Rabinowitz et al.
349.	01/23/2003	US 2003/0017115	Rabinowitz et al.
350.	01/23/2003	US 2003/0017116	Rabinowitz et al.
351.	01/23/2003	US 2003/0017117	Rabinowitz et al.
352.	01/23/2003	US 2003/0017118	Rabinowitz et al.
353.	01/23/2003	US 2003/0017119	Rabinowitz et al.
354.	01/23/2003	US 2003/0017120	Rabinowitz et al.
355.	1/30/2003	US 2003/0021753	Rabinowitz et al.
356.	01/30/2003	US 2003/0021754	Rabinowitz et al.
357.	01/30/2003	US 2003/0021755	Hale et al.
358.	02/20/2003	US 2003/0035776	Hodges et al.
359.	05/15/2003	US 2003/0091511	Rabinowitz et al.
360.	05/27/2004	US 2004/010148	Hale et al.
361.	07/31/2003	US 2003/0138382	Rabinowitz
362.	11/06/2003	US 2003/0206869	Rabinowitz et al.
363.	01/15/2004	US 2004/0009128	Rabinowitz et al.
364.	05/20/2004	US 2004/0096402	Hodges et al.

**EXAMINER:** 

DATE CONSIDERED:

### INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

	5heet 15 01 20
Docket Number: 00067.01R	Application Number: 10/718,982
Applicant: HALE et al.	
Filing Date: 11/20/2003	Group Art Unit: Net yet known

30	65.	06/03/2004	US 2004/0105818	Hale et al.
30	66.	06/03/2004	US 2004/0105819	Hale et al.
30	67.	07/01/2004	US 2004/0126326	Rabinowitz et al.
30	68.	07/01/2004	US 2004/0126327	Rabinowitz et al.
30	69.	07/01/2004	US 2004/0126328	Rabinowitz et al.
3	70.	07/01/2004	US 2004/0126329	Rabinowitz et al.
3	71.	07/01/2004	US 2004/0127481	Rabinowitz et al.
3	72.	07/01/2004	US 2004/0127490	Rabinowitz et al.
3	73.	08/12/2004	US 2004/0156788	Rabinowitz et al.
3	74.	08/12/2004	US 2004/0156789	Rabinowitz et al.
3	75.	8/12/2004	US 2004/0156790	Rabinowitz et al.
3	76.	08/12/2004	US 2004/0156791	Rabinowitz et al.

#### FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
_	377.	01/02/1996	CA 2,152,684	Canada			- 100
	378.	02/23/1994	CN 1082365	China			Abstract only
	379.	03/18/1998	CN 1176075	China			Abstract
	380.	11/11/1981	EP 0 039 369	Europe			
	381.	07/13/1988	EP 0 274 431	Europe			-
	382.	08/10/1988	EP 0 277 519	Europe			
	383.	03/14/1990	EP 0 358 114	Europe			
	384.	06/05/1991	EP 0 430 559	Europe			
	385.	07/01/1992	EP 0 492 485	Europe			
	386.	07/20/1994	EP 0 606 486	Europe			
	387.	02/13/1996	EP 0 734 719	Europe			
	388.	12/29/1999	EP 0 967 214	Europe			
	389.	03/07/2001	EP 1 080 720	Europe			

**EXAMINER:** 

DATE CONSIDERED:

### INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 00067.01R

Application Number: 10/718,982

Applicant: HALE et al.

Filing Date: 11/20/2003

Group Art Unit: Net yet known

·	390.	02/06/2002	EP 1 177 793	Europe		
	391.	05/18/2000	DE 198 54 007	Germany		
<del></del>	392.	01/29/1938	GB 502 761	Great Britain		
	393.	08/22/1962	GB 903 866	Great Britain		
	394.	09/11/1974	GB 1 366 041	Great Britain		
	395.	05/18/1983	GB 2 108 390	Great Britain		
	396.	01/25/1984	GB 2 122 903	Great Britain		
	397.	05/21/1947	FR 921 852 A	France		
	398.	01/04/1980	FR 2 428 068 A	France		
	399.	02/14/1985	WO 85/00520	WIPO		
	400.	11/03/1988	WO 88/08304	WIPO		
•	401.	03/22/1990	WO 90/02737	WIPO		
	402.	07/12/1990	WO 90/07333	WIPO		
	403.	06/13/1991	WO 91/07947	WIPO		
	404.	12/12/1991	WO 91/18525	WIPO		
	405.	04/16/1992	WO 92/05781	WIPO	_	
	406.	09/17/1992	WO 92/15353	WIPO		
	407.	11/12/1992	WO 92/19303	WIPO		
	408.	07/08/1993	WO 93/12823	WIPO		
	409.	05/11/1994	WO 94/09842	WIPO		
	410.	08/04/1994	WO 94/16717	WIPO		
	411.	08/04/1994	WO 94/16757	WIPO		
	412.	08/04/1994	WO 94/16759	WIPO		
	413.	08/04/1994	WO 94/17369	WIPO		
	414.	08/04/1994	WO 94/17370	WIPO		
	415.	12/08/1994	WO 94/27576	WIPO		
	416.	12/08/1994	WO 94/27653	WIPO		
	417.	11/23/1995	WO 95/31182	WIPO		
	418.	01/04/1996	WO 96/00069	WIPO		
	419.	01/04/1996	WO 96/00070	WIPO		
	420.	01/04/1996	WO 96/00071	WIPO		

**EXAMINER:** 

DATE CONSIDERED:

### INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 00067.01R Ap

Application Number: 10/718,982

Applicant: HALE et al.

Filing Date: 11/20/2003 Group Art

Group Art Unit: Net yet known

421.	04/04/1996	WO 96/10663	WIPO	
422.	04/11/1996	WO 96/09846	WIPO	
423.	05/09/1996	WO 96/13161	WIPO	
424.	05/09/1996	WO 96/13290	WIPO	
425.	05/09/1996	WO 96/13291	WIPO	
426.	05/09/1996	WO 96/13292	WIPO	
427.	10/03/1996	WO 96/30068	WIPO	
428.	10/10/1996	WO 96/31198	WIPO	
429.	11/28/1996	WO 96/37198	WIPO	
430.	05/09/1997	WO 97/16181	WIPO	
431.	05/22/1997	WO 97/17948	WIPO	
432.	07/03/1997	WO 97/23221	WIPO	
433.	08/07/1997	WO 97/27804	WIPO	
434.	09/04/1997	WO 97/31691	WIPO	
435.	10/02/1997	WO 97/35562	WIPO	
436.	10/09/1997	WO 97/36574	WIPO	
437.	12/31/1997	WO 97/49690	WIPO	
438.	01/22/1998	WO 98/02186	WIPO	
439.	04/23/1998	WO 98/16205	WIPO	
440.	05/28/1998	WO 98/22170	WIPO	
441.	07/09/1998	WO 98/29110	WIPO	
442.	07/23/1998	WO 98/31346	WIPO	
443.	08/13/1998	WO 98/34595	WIPO	
444.	08/27/1998	WO 98/36651	WIPO	
445.	08/27/1998	WO 98/37896	WIPO	
446.	02/04/1999	WO 99/04797	WIPO	
447.	04/08/1999	WO 99/16419	WIPO	
448.	05/20/1999	WO 99/24433	WIPO	
449.	07/29/1999	WO 99/37347	WIPO	
450.	07/29/1999	WO 99/37625	WIPO	
451.	09/10/1999	WO 99/44664	WIPO	

**EXAMINER:** 

DATE CONSIDERED:

### INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 00067.01R

Application Number: 10/718,982

Applicant: HALE et al.

Filing Date: 11/20/2003 Group Art Unit: Net yet known

	452.	11/04/1999	WO 99/55362	WIPO	
	453.	11/25/1999	WO 99/59710	WIPO	
	454.	12/16/1999	WO 99/64094	WIPO	
	455.	01/06/2000	WO 00/00176	WIPO	
	456.	01/06/2000	WO 00/00215	WIPO	
	457.	01/06/2000	WO 00/00244	WIPO	
	458.	04/13/2000	WO 00/19991	WIPO	
	459.	05/18/2000	WO 00/27363	WIPO	
	460.	05/18/2000	WO 00/27359	WIPO	
	461.	05/18/2000	WO 00/27363	WIPO	
	462.	05/25/2000	WO 00/29053	WIPO	
	463.	05/25/2000	WO 00/29167	WIPO	
	464.	06/22/2000	WO 00/35417	WIPO	
	465.	07/06/2000	WO 00/38618	WIPO	
	466.	08/03/2000	WO 00/44350	WIPO	
	467.	08/03/2000	WO 00/44730	WIPO	
	468.	09/08/2000	WO 00/51491	WIPO	
	469.	09/17/2000	WO 00/47203	WIPO	
-	470.	11/02/2000	WO 00/64940	WIPO	
	471.	11/09/2000	WO 00/066084	WIPO	
	472.	11/09/2000	WO 00/66106	WIPO	
	473.	11/09/2000	WO 00/66206	WIPO	
	474.	12/07/2000	WO 00/72827	WIPO	
	475.	12/21/2000	WO 00/76673	WIPO	
	476.	01/25/2001	WO 01/05459	WIPO	
	477.	03/01/2001	WO 01/13957	WIPO	
	478.	03/15/2001	WO 01/17568	WIPO	
	479.	03/22/2001	WO 01/19528	WIPO	
•	480.	04/26/2001	WO 01/29011	WIPO	
	481.	05/10/2001	WO 01/32144	WIPO	
	482.	06/14/2001	WO 01/41732	WIPO	
<del></del>				<del></del>	<del></del>

**EXAMINER:** 

DATE CONSIDERED:

## INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 00067.01R	Application Number: 10/718,982
DOCKET NUMBER. 00007.01K	Application Number, 10/716,362

Applicant: HALE et al.

Filing Date: 11/20/2003 Group Art Unit: Net yet known

483.	12/20/2001	WO 01/95903	WIPO		
484.	01/03/2002	WO 02/00198	WIPO		
 485.	03/28/2002	WO 02/24158	WIPO		
486.	03/28/2002	WO 02/24158	WIPO		
 487.	07/25/2002	WO 02/56866	WIPO		

#### OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

		(
Examiner Initials	Ref. No.	Title
	488.	Anderson, M.E. (1982). "Recent Advances in Methodology and Concepts for Characterizing Inhalation Pharmacokinetic Parameters in Animals and Man," <i>Drug Metabolism Reviews</i> . 13(5):799-826.
	489.	Bennett, R. L. et al. (1981). "Patient-Controlled Analgesia: A New Concept of Postoperative Pain Relief," <i>Annual Surg.</i> 195(6):700-705.
	490.	Benowitz (1994). "Individual Differences in Nicotine Kinetics and Metabolism in Humans," NIDA Research Monography, 2 pages.
	491.	BP: Chemicals Products-Barrier Resins (1999). located at <a href="http://www.bp.com/chemicals/products/product.asp">http://www.bp.com/chemicals/products/product.asp</a> (visited on August 2, 2001), 8 pages.
,	492.	Brand, P. et al. (June 2000). "Total Deposition of Therapeutic Particles During Spontaneous and Controlled Inhalations," <i>Journal of Pharmaceutical Sciences</i> . 89(6):724-731.
	493.	Campbell, Fiona A. et al. (2001). "Are cannabinoids an effective and safe treatment options in the management of pain? A qualitative systemic review." Vol. 323 (7303): 13-16.
	494.	Carroll, M.E. et al. (1990), "Cocaine-Base Smoking in Rhesus Monkey: Reinforcing and Physiological Effects," Psychopharmacology (Berl) 102:443-450.
	495.	Cichewicz, Diana L. et al. (May 1999) "Enhancement of mu opioid antinociception by oral DELTA 9 – tetrahydrocannabinol: Dose response analysis and receptor identification" Journal of Pharmacology and Experimental Therapeutics Vol 289 (2): 859-867.
	496.	Clark, A. and Byron, P. (1986). "Dependence of Pulmonary Absorption Kinetics on Aerosol Particle Size," Z. Erkrank. 166:13-24.
	497.	Dallas, C. et al. (1983). "A Small Animal Model for Direct Respiratory and Hemodynamic Measurements in Toxicokinetic Studies of Volatile Chemicals," <u>Devlopments in the Science and Practice of Toxicology.</u> Hayes, A. W. et al. eds., Elsevier Science Publishers, New York. pp.419-422.

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conformance and not considered. Include a copy of this form with next	

## INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

	Silect 10 01 20
Docket Number: 00067.01R	Application Number: 10/718,982
Applicant: HALE et al.	
Filing Date: 11/20/2003	Group Art Unit: Net yet known

	1-
498.	Darquenne, C. et al. (1997). "Aerosol Dispersion in Human Lung: Comparison Between Numerical Simulations and Experiments for Bolus Tests," <i>American Physiological Society</i> . 966-974.
499.	Database Biosis "Online!" Biosciences Information Service, Philadelphia, PA 1979, Knight, V. et al., "Amantadine aerosol in humans", database accession no. PREV 198069035552 abstract, &Antimicrobial Agents and Chemotherapy 16(5):572-578.
500.	Database Biosis "Online!" Biosciences Information Service, Philadelphia, PA 1979, Wilson. S.Z. et al., "Amatadine Aerosol Particle Aerosol Generation and Delivery to Man" Database accession no. PREV198069008137, abstract & Proceedings of the Society for Experimental Biology and Medicine 161(3):350-354.
501.	Database WPI, Section CH, Week 198941, Derwent Publications Ltd., London, GB; Class B07, AN 1989-297792 AP002230849 & JP 01 221313 (NIPPON CREATE 1(K), 09/04/89, abstract.
502.	Davies, C. N. et al. (May 1972). "Breathing of Half-Micron Aerosols," <i>Journal of Applied Physiology</i> . 32(5):591-600.
503.	Dershwitz, M., M.D., et al. (September 2000). "Pharmacokinetics and Pharmacodynamics of Inhaled versus Intravenous Morphine in Healthy Volunteers," <i>Anesthesiology</i> . 93(3): 619-628.
504.	Drugs Approved by the FDA -Drug Name: Nicotrol Inhaler (2000) located at <a href="http://www.centerwatch.com/patient/drugs/dru202.html">http://www.centerwatch.com/patient/drugs/dru202.html</a> (Visited on August 2, 2001), 2 pages.
505.	Feynman, R.P. et al. (1964). "Chapter 32: Refractive Index of Dense Materials" <u>The Feynman Lectures on Physics: Mainly Electromagnetism and Matter.</u> Addison-Wesley: Publishing Company, Inc., Reading, Massachusetts: pp. 32-1 - 32-13.
506.	Finlay, W. H. (2001). "The Mechanics of Inhaled Pharmaceutical Aerosols", Academic Press: San Diego Formula 2.39. pp.3-14 (Table of Contents). pp. v-viii.
507.	Gonda, I. (1991). "Particle Deposition in the Human Respiratory Tract," Chapter 176, The Lung. Scientific Foundations. Crystal R.G. and West, J.B. (eds.), Raven Publishers, New York. pp. 2289-2294.
508.	Graves, D. A. et al. (1983). "Patient-Controlled Analgesia," Annals of Internal Medicine. 99:360-366.
509.	Anonymous, (June 1998) <u>Guidance for Industry: Stability testing of drug substances and products</u> , U.S. Department of Health and Human Services, FDA, CDER, CBER, pp. 1-110.
510.	Hatsukami D., et al. (May 1990) "A Method for Delivery of Precise Doses of Smoked Cocaine-Base to Human." <i>Pharmacology Biochemistry &amp; Behavior</i> . 36(1):1-7.
511.	Heyder, J. et al. (1986). "Deposition of Particles in the Human Respiratory Tract in the Size Range 0.005-15 μm," J. Aerosol Sci. 17(5):811-822.
512.	Huizer, H. (1987). "Analytical Studies on Illicit Heron. V. Efficacy of Volitization During Heroin Smoking." <i>Pharmaceutisch Weekblad Scientific Edition</i> . 9(4):203-211.
513.	Hurt, R. D., MD and Robertson, C. R., PhD, (October 1998). "Prying Open the Door to the Tobacco Industry's Secrets About Nicotine: The Minnesota Tobacco Trial," <i>JAMA</i> 280(13):1173-1181.

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conformance and not considered. Include a copy of this form with next	conforms with MPEP 609. Draw a line through the citation if not in communication to applicant.

## INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

	SHEEL 19 01 20
Docket Number: 00067.01R	Application Number: 10/718,982
Applicant: HALE et al.	
Filing Date: 11/20/2003	Group Art Unit: Net yet known

514.	Hwang, S. L. (June 1999). "Artificial Nicotine Studied: R. J. Reynolds Seeks to Develop Drugs that Mimic Tobacco's Potent Effects on Brain," Wall Street Journal, 3 pages.
515.	James, A.C. et al., (1991). "The Respiratory Tract Deposition Model Proposed by the ICRP Task Group," <i>Radiation Protection Dosimetry</i> , 38(1/3):159-165.
516.	Kim, M. H. and Patel, D.V. (1994). "BOP' As a Reagent for Mild and Efficient Preparation of Esters," <i>Tet. Letters</i> 35:5603-5606.
517.	Lichtman, A. H. et al. (1996). "Inhalation Exposure to Volatilized Opioids Produces Antinociception in Mice," Journal of Pharmacology and Experimental Therapeutics. 279(1):69-76 XP-001118649.
518.	Lichtman, A. H. et al. (2000). "Pharmacological Evaluation of Aerosolized Cannabinoids in Mice" European Journal of Pharmacology, Vol. 399, No. 2-3: 141-149.
519.	Lopez, K. (July 1999). "UK Researcher Develops Nicotinic Drugs with R. J. Reynolds," located at <a href="http://www.eurekalert.org/pub_releases/1999-07/UoKM-Urdn-260799.php">http://www.eurekalert.org/pub_releases/1999-07/UoKM-Urdn-260799.php</a> (visited on October 1, 2002), 1 page.
520.	Martin, B. R. and Lue, L. P. (May/June 1989). "Pyrolysis and Volatilization of Cocaine," <i>Journal of Analytical Toxicology</i> 13:158-162.
521.	Mattox, A.J. and Carroll, M.E. (1996). "Smoked Heroin Self-Administration in Rhesus Monkeys," <i>Psychopharmacology</i> 125:195-201.
522.	McCormick, A.S.M., et al., "Bronchospasm During Inhalation of Nebulized Midazolam," British Journal of Anesthesia, Vol.80 (4), April 1988, pgs. 564-565 XP001119488.
523.	Meng, Y. et al. (1997). "Inhalation Studies with Drugs of Abuse", NIDA Research Monogragh 173:201-224.
524.	Meng, Y., et al. (1999). "Pharmacological effects of methamphetamine and other stimulants via inhalation exposure," <i>Drug and Alcohol Dependence</i> . 53:111-120.
525.	Office Action mailed 8/13/2003 for US application 10/153,313 filed 05/21/2002 "Delivery of Benzodiazepines Through an Inhalation Route".
526.	Office Action mailed 12/04/2003 for US application 10/057,198 filed 10/26/2001 "Method and Device for Delivering a Physiologically Active Compound."
527.	Office Action mailed 12/15/2003 for US application 10/057,197 filed 10/26/2001 "Aerosol Generating Device and Method"
528.	Pankow, J. F. et al. (1997). "Conversion of Nicotine in Tobacco Smoke to Its Volatile and Available Free-Base Form through the Action of Gaseous Ammonia," <i>Environ. Sci. Technol.</i> 31:2428-2433.
529.	Pankow, J. (March 2000). ACS Conference-San Francisco-3/26/00. Chemistry of Tobacco Smoke. pp. 1-8.
530.	Poochikian, G. and Bertha, C.M. (2000). "Inhalation Drug Product Excipient Controls: Significance and Pitfalls," <i>Resp. Drug Deliv.</i> VII: 109-115.

EXAMINER:	DATE CONSIDERED:			
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.				

PTO/SB/08 (2-92) Sheet 20 of 20

# Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

	5HCC1 20 01 20
Docket Number: 00067.01R	Application Number: 10/718,982
Applicant: HALE et al.	
Filing Date: 11/20/2003	Group Art Unit: Net yet known

531.	ScienceDaily Magazine, (July 1999). "University of Kentucky Researcher Develops Nicotinic Drugs with R. J. Reynolds," located at <a href="http://www.sciencedaily.com/releases/1999/07/990728073542.htm">http://www.sciencedaily.com/releases/1999/07/990728073542.htm</a> (visited on September 23, 2002), 2 pages.
532.	Seeman, J. et al. (1999). "The Form of Nicotine in Tobacco. Thermal Transfer of Nicotine and Nicotine Acid Salts to Nicotine in the Gas Phase," J. Agric. Food Chem. 47(12):5133-5145.
533.	Sekine, H. and Nakahara, Y. (1987). "Abuse of Smoking Methamphetamine Mixed with Tobacco: 1. Inhalation Efficiency and Pyrolysis Products of Methamphetamine," <i>Journal of Forensic Science</i> 32(5):1271-1280.
534.	Streitwieser, A. and Heathcock, C. H. eds., (1981). <u>Introduction to Organic Chemistry</u> . Second edition, Macmillan Publishing Co., Inc., New York, pp. ix-xvi. (Table of Contents).
535.	Tsantilis, S. et al. (2001). "Sintering Time for Silica Particle Growth," Aerosol Science and Technology 34:237-246.
536.	Vapotronics, Inc. (1998) located at <a href="http://www.vapotronics.com.au/banner.htm">http://www.vapotronics.com.au/banner.htm</a> , 11 pages, (visited on June 5, 2000).
537.	Vaughan, N.P. (1990). "The Generation of Monodisperse Fibres of Caffeine" J. Aerosol Sci. 21(3): 453-462.
538.	Ward, M. E. MD, et al. (December 1997). "Morphine Pharmacokinetics after Pulmonary Administration from a Novel Aerosol Delivery System," <i>Clinical Pharmacology &amp; Therapeutics</i> 62(6):596-609.
539.	Williams, S. (February 1999). "Rhone-Poulenc Rorer Inc. and Targacept Inc. Announce Alliance to Develop New Drugs to Treat Alzheimer's and Parkinson's Diseases" located at http://www.rpr.rpna.com/ABOUT_RPR/pressrels/1999/990209-targa.html (last visited on January 28, 2000) 1 page.
540.	Wood, R.W. et al. (1996). "Generation of Stable Test Atmospheres of Cocaine Base and Its Pyrolyzate, Methylecgonidine, and Demonstration of Their Biological Activity." <i>Pharmacology Biochemistry &amp; Behavior</i> . 55(2):237-248.

EXAMINER:	DATE CONSIDERED: